S-iii
|
|
S-1
|
|
S-7
|
|
S-8
|
|
S-31
|
|
S-32
|
|
S-33
|
|
S-34
|
|
S-35
|
|
S-37
|
|
S-39
|
|
S-39
|
|
S-39
|
|
S-40
|
|
S-40
|
Summary
|
1
|
Documents Incorporated by Reference
|
2
|
Where You Can Find More Information
|
2
|
Forward-Looking Statements
|
3
|
Use of Proceeds
|
4
|
Exchange Rate Information
|
5
|
Price Range of our Ordinary Shares
|
6
|
Price Range of our ADSs
|
7
|
Ratio of Earnings to Fixed Charges
|
8
|
Description of Share Capital
|
9
|
Description of American Depositary Shares
|
14
|
Description of Debt Securities
|
17
|
Description of Warrants
|
30
|
Description of Units
|
32
|
Taxation
|
33
|
Plan of Distribution
|
34
|
Experts
|
37
|
Legal Matters
|
37
|
Enforceability of Civil Liabilities
|
38
|
This summary highlights selected information contained elsewhere in this prospectus supplement, the accompanying prospectus, any free writing prospectus that we have been authorized to use and the documents incorporated by reference herein and in the accompanying prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our ADSs, our Ordinary Shares or the Warrants. You should read this summary together with the entire prospectus, including the risks related to our most advanced therapeutic candidates, BL-1020, BL-1040, BL-5010, BL-7040, BL-8040 and BL-1021, our business, our industry, investing in our Ordinary Shares and our location in Israel, that we describe under “Risk Factors” in this prospectus supplement and our consolidated financial statements and the related notes, which are incorporated by reference herein, before making an investment in our ADSs, our Ordinary Shares or the Warrants.
Our Business
We are a clinical stage biopharmaceutical development company dedicated to identifying, in-licensing and developing therapeutic candidates that have advantages over currently available therapies or that address unmet medical needs. Our current development pipeline consists of six clinical-stage therapeutic candidates: BL-1020, an orally available drug that we believe may be the first antipsychotic therapeutic to improve cognitive function in schizophrenia patients; BL-1040, a novel polymer solution for use in the prevention of cardiac remodeling and congestive heart failure following an acute myocardial infarction, or AMI; BL-5010, a customized, pen-like applicator containing a novel formulation of two acids, which is being developed for the non-surgical removal of skin lesions; BL-7040, an oligonucleotide for the treatment of Inflammatory Bowel Disease (IBD); BL-8040, a peptide for the treatment of Acute Myeloid Leukemia (AML) and other hematological cancers; and BL-1021, a new chemical entity in development for the treatment of neuropathic pain, or pain that results from damage to nerve fibers. In addition, we have eight therapeutic candidates in the preclinical stages of development. We generate our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a relatively high probability of therapeutic and commercial success. None of our therapeutic candidates has been approved for marketing and, to date, there have been no commercial sales of any of our therapeutic candidates. Our strategy includes commercializing our therapeutic candidates through out-licensing arrangements with biotechnology and pharmaceutical companies and evaluating, on a case by case basis, the commercialization of our therapeutic candidates independently.
Our Product Pipeline
The table below summarizes our current pipeline of therapeutic candidates, as well as the target indication and status of each candidate.
|
BL-1020
Our first lead therapeutic candidate, BL-1020, is in development for schizophrenia, a chronic, severe and disabling brain disorder that affects approximately 1% of the U.S. adult population as reported by the National Institute of Mental Health. Schizophrenia patients are typically treated with one of several commercially available antipsychotics, all of which are associated with side effects that reduce patient compliance and do not address the deterioration of cognitive function that affects the daily lives of schizophrenia patients. Despite these drawbacks, the three most commonly used antipsychotics, Risperdal, Zyprexa and Seroquel, reached aggregate sales of approximately $7.1 billion in the United States in 2009, based on the annual reports filed with the U.S. Securities and Exchange Commission, or SEC, by each of Johnson & Johnson, Eli Lilly and Company and AstraZeneca Pharmaceuticals LP, the companies that market those drugs.
BL-1020 is an orally available drug that effectively reduces psychotic symptoms and may also improve cognition. BL-1020 targets the imbalance of two key neurotransmitters implicated in schizophrenia, dopamine and gamma aminobutyric acid, or GABA. We believe that the reduction in psychotic symptoms is attributable to BL-1020’s dopamine antagonism while the improvement in cognition may result from BL-1020’s GABAergic activity.
In our 363-patient phase 2b EAGLE (Effective Anti-psychosis via GABA Level Enhancement) study which was completed in July 2009, BL-1020 matched the antipsychotic efficacy of Risperdal, one of the leading approved antipsychotics, without evidence of the metabolic side effects associated with the use of atypical antipsychotics. Most significantly, BL-1020 demonstrated a clinically relevant and statistically significant improvement in cognition. Currently, there is no commercially available antipsychotic that improves cognitive function and this remains an important unmet medical need in the treatment of schizophrenia and other psychiatric and neurological diseases. In June 2011, we commenced the CLARITY clinical trial with respect to BL-1020. The CLARITY trial is designed to be a randomized, double-blind trial to examine both acute (6 weeks) and long-term (24 weeks) cognitive and antipsychotic efficacy, safety and tolerability of BL-1020 on patients with acute schizophrenia. In May 2011, we received approval to commence the CLARITY trial at 14 trial sites in Romania. The initiation of the trial in Romania took place in May 2011 and the first patient was treated in June 2011. In November 2011 we received approval from the Indian regulatory authorities and the Indian local ethics committees to commence the trial at 18 additional clinical sites in India. We started recruitment in November 2011 and the first patient was treated in December 2011. We anticipate reporting results from an interim analysis of the CLARITY trial in March 2013.
In June 2010, we entered into an exclusive, royalty-bearing out-licensing arrangement with Cypress Bioscience with regard to BL-1020, covering the United States, Canada and Mexico, which became effective in August 2010. We received an upfront fee of $30.0 million from Cypress Bioscience upon the effectiveness of the agreement. We are obligated to pay to Bar Ilan Research and Development and Ramot at Tel Aviv University (Ramot), collectively, a royalty payment equal to 22.5% of the net consideration we receive from the out-licensing of BL-1020. We paid Bar Ilan Research and Development and Ramot $6.75 million, in the aggregate, from the $30.0 million upfront fee. We also paid the Office of the Chief Scientist of Israel’s Ministry of Industry, Trade and Labor, or the OCS, $3.0 million as partial repayment of grants previously received for the BL-1020 development program.
In January 2011, Royalty Pharma acquired Cypress Bioscience. After the acquisition, we had a number of discussions with Cypress Bioscience and Royalty Pharma and they indicated to us that as a result of a change in their strategy, they believed it was in the best interest of BL-1020’s future commercial potential to consolidate the worldwide rights with our company. Cypress Bioscience expressed its desire that development of BL-1020 continue in a manner that both optimized Cypress Bioscience’s investment in BL-1020 and provided the best long-term commercialization potential. We believe that reacquiring BL-1020 was the best alternative at that time to ensure the timely development of BL-1020 and represented a significant opportunity for our company. Accordingly, on May 10, 2011, we entered into a rights reacquisition agreement with Cypress Bioscience. Under the terms and conditions of the rights reacquisition agreement, the out-license agreement terminated on May 31, 2011, and we reacquired all of the rights to develop and commercialize BL-1020 on that date. In consideration for the reacquisition of the rights, we agreed to pay Cypress Bioscience a royalty equal to 1% of the future net sales of BL-1020, if any, by us, our affiliates or our sublicensees. Notwithstanding the foregoing, the aggregate royalty payment shall not exceed $80.0 million. In addition, we agreed to pay Cypress Bioscience $10.0 million payable solely from amounts we receive, if any, pursuant to future agreements relating to the further development or commercialization of a product containing BL-1020, either alone or with other therapeutically active ingredients. In connection with the payment, we are required to pay Cypress Bioscience 10% of all payments under any such agreement but in any event, not more than $10.0 million. If any such agreement requires that we incur the costs of certain proposed clinical trials of BL-1020, the payment schedule will be subject to certain deferrals. We have no other outstanding material obligations to Cypress Bioscience under the original out-license agreement, other than standard indemnification obligations. We intend to continue to consider potential out-licensing opportunities for BL-1020, as well as the potential to develop and commercialize BL-1020 internally.
|
BL-1040
Our second lead therapeutic candidate, BL-1040, is a novel resorbable polymer solution for use in the reduction or prevention of cardiac remodeling and congestive heart failure in patients who suffered an AMI. Reducing or preventing cardiac remodeling following an AMI may reduce or prevent transition to congestive heart failure and/or improve patient survival over the long term. Following an AMI, BL-1040 is administered via intracoronary deployment. Within the damaged cardiac tissue, the liquid BL-1040 transitions into a gel within the infarcted cardiac tissue and forms a “scaffold” that supports, retains the shape of, and enhances the mechanical strength of the heart muscle during the recovery phase following an AMI. The data from our preclinical studies suggest that BL-1040 improves the normal functioning of the heart. After consultation by our sublicensee Ikaria (see below) with the FDA, BL-1040 is being developed as a class III medical device under the FDA’s pre-marketing approval, or PMA, regulatory pathway.
In July 2009, we entered into an exclusive, worldwide out-licensing arrangement with a wholly-owned subsidiary of Ikaria, Inc., or Ikaria, with regard to BL-1040. Under the arrangement, Ikaria is obligated to use commercially reasonable efforts to complete clinical development of, and to commercialize, BL-1040 or a product related thereto. To date, we have received $17.0 million from Ikaria and we are entitled to receive up to an additional $265.5 million from Ikaria upon achievement of certain development, regulatory, and commercial milestones. In addition, we are entitled to receive from Ikaria royalties from net sales of any product developed under the arrangement. We are obligated to pay 28% of all net consideration received under this arrangement to B.G. Negev Technologies, the party from which we in-licensed BL-1040 in 2004. We have agreed to pay Ramot a portion of the payments we make to B.G. Negev Technologies in connection with the in-license arrangement to satisfy contractual obligations between B.G. Negev Technologies and Ramot with respect to certain intellectual property rights to the licensed technology. We have also agreed to indemnify Ramot and certain of its related parties in connection with our use of the technology we in-licensed from B.G. Negev Technologies.
In December 2011 Ikaria commenced PRESERVATION 1, a CE Mark registration clinical trial of BL-1040 (now called “Bioabsorbable Cardiac Matrix,” or BCM by Ikaria). PRESERVATION 1 aims to evaluate the safety and effectiveness of BL-1040 (BCM) for reduction or prevention of ventricular remodeling and congestive heart failure when administered following AMI. The trial is a placebo-controlled, randomized, double-blind, multi-country and multi-center trial including approximately 300 patients who currently are expected to be recruited across over 90 sites. The BCM device will be administered to subjects who had successful percutaneous coronary intervention with stent placement after ST-segment elevation myocardial infarction (STEMI) and they will then be monitored for six months.
BL-5010
Our third clinical-stage project, BL-5010, comprises a customized, pen-like applicator containing a novel formulation of two acids, which is being developed for the non-surgical removal of skin lesions. These two acids have already been approved for use in cosmetics. If approved, BL-5010 would be a convenient alternative to invasive, painful and expensive removal treatments for skin lesions and may allow for histological examination. Because treatment with BL-5010 is non-invasive, we believe BL-5010 poses minimal infection risk, and requires no anesthesia or bandaging. BL-5010 recently received European confirmation from the British Standards Institution Notified Body (BSI) in the UK, of the regulatory pathway classification as a Class IIa medical device.
In June 2009, we announced the initiation of a phase 1/2 clinical trial in 60 patients with seborrheic keratosis in Germany and the Netherlands to assess the safety and efficacy of BL-5010. The study was also designed to assess the feasibility of preserving the cellular structure of skin lesions for subsequent histological exams. The study was completed in September 2010, and positive results were announced in December 2010. The results of the trial show that for 96.7% of patients, the treated lesion fell off within 30 days of a single application of BL-5010. The results also showed that BL-5010 has a good safety profile, as no persistent irreversible adverse effects were observed at the treated site. We are currently planning to commence a pivotal CE-Mark registration study for European approval in 2013.
|
BL-7040
Our fourth clinical-stage therapeutic candidate, BL-7040, is an orally available, synthetic oligonucleotide which we intend to develop for the treatment of IBD. This synthetic oligonucleotide consisting of a sequence of nucleic acids, the building blocks of genetic material such as DNA, has unique dual activity. Multiple preclinical in vivo studies have shown the safety and efficacy of BL-7040. Previous phase 1b and 2a clinical studies were completed with no major adverse events being reported. We intend to develop the compound for the treatment of IBD. We are currenly carryng out a phase 2 study of BL-7040 to evaluate the effectiveness of BL-7040 for the treatment of IBD, at five sites in Israel.
BL-8040
Our fifth clinical-stage therapeutic candidate, BL-8040, is a short peptide that functions as a high-affinity antagonist for CXCR4, which we intend to develop for AML and other hematological cancers. CXCR4 is a chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of tumor to other organs) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its over-expression often correlates with poor prognosis. We believe BL-8040 works by mobilizing cancer cells from the bone marrow — exposing them to anti-cancer therapies — and by inducing apoptosis of tumor cells. Multiple pre-clinical studies have shown the safety and efficacy of BL-8040. These studies have shown that BL-8040 is effective, both alone and in combination with various anti-cancer drugs. In a Phase 1/2, open-label, dose escalation, safety and efficacy clinical trial in 16 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile and was well tolerated at all doses tested. On the basis of data obtained from this study, the FDA has approved an Investigational New Drug application. We plan to commence a phase 2 clinical trial in the first half of 2013.
BL-1021
Our sixth clinical-stage therapeutic candidate, BL-1021, is a new chemical entity in development for the treatment of neuropathic pain, or pain that results from damage to nerve fibers. Multiple preclinical in vitro and in vivo studies have shown the safety and efficacy of BL-1021. BL-1021 showed significant reduction in symptoms of neuropathic pain with an enhanced safety profile.
In December 2011, we completed a phase 1a clinical trial to assess safety, tolerability and pharmacokinetics of a single administration of BL-1021 at doses between 10mg and 80mg in healthy volunteers. This clinical trial was a single-site, double-blind, placebo controlled study, carried out at the Hadassah Clinical Research Center in Jerusalem, Israel. Study results demonstrated that a single administration of BL-1021 in the dose range examined was safe and well tolerated, with no significant changes noted in vital signs, ECG or laboratory safety parameters at any dose when compared either to baseline measurements or to the placebo group. In addition, preliminary modeling of the pharmacokinetic data collected in this trial predicts that a once daily administration of BL-1021 at the dose levels assessed will enable reaching effective doses in patients. We are currently evaluating potential development collaborations with other parties in order to continue development of this compound.
Our Product Development Approach
As part of our business strategy, we continuously source, evaluate and in-license therapeutic candidates. We establish and maintain close relationships with research institutes, academic institutions and biotechnology companies in Israel and, more recently, in other countries to identify and in-license therapeutic candidates. Before in-licensing, each therapeutic candidate must pass through our thorough screening process. We evaluate each compound’s potential for success by looking at the candidate’s efficacy, safety profile, total estimated development costs, technological novelty, patent status, market need and approvability, among other information. Our Scientific Advisory Board and disease-specific third-party advisors are active in evaluating each therapeutic candidate. Our approach is consistent with our objective of proceeding only with therapeutic candidates that we believe exhibit a relatively high probability of therapeutic and commercial success. To date, we estimate we have evaluated over 2,000 compounds, and we have presented more than 60 candidates to our Scientific Advisory Board for consideration, initiated development of 42 therapeutic candidates and terminated 28 feasibility programs.
When possible, we make use of third-party funding to develop early-stage therapeutic candidates. In January 2005, we entered into an agreement with the OCS to operate a biotechnology incubator. We develop certain of our in-licensed candidates with financial assistance from the OCS and have received approximately $13.6 million as of September 30, 2012 in the form of loans that are forgiven unless a project reaches commercialization. We have also received $5.5 million in grants from the OCS outside of the incubator agreement as of September 30, 2012. We are not required to repay grants for terminated projects. Of our 14 current development projects, eight have been or are approved to be funded by the OCS, either directly or through our incubator: BL-1020, BL-1021, BL-1040, BL-5040, BL-6030/1, BL-7020, BL-7040 and BL-7050. Other than BL-7040, all of these projects were also funded or are approved to be funded through our incubator. In addition, in January 2007 we entered into an agreement with one of our existing shareholders, Pan Atlantic Bank and Trust Limited, or Pan Atlantic, pursuant to which Pan Atlantic provided us with grants totalling $5.0 million to be used in connection with the in-licensing and development of early development stage therapeutic candidates.
|
Our Strategy
Our objective is to be a leader in developing and commercializing innovative pharmaceutical, medical device and biopharmaceutical products.
The key elements of our strategy include the following:
|
|
•
|
support the successful development and commercialization of BL-1040 by Ikaria.
|
|
|
|
•
|
assess the timing and conditions for the continued development and commercialization of BL-1020.
|
|
|
|
•
|
commercialize additional therapeutic candidates through out-licensing arrangements or, where appropriate, by ourselves.
|
|
|
|
•
|
design development programs that reach critical decisions quickly.
|
|
|
|
•
|
use our expertise and proprietary screening methodology to evaluate in-licensing opportunities.
|
|
|
•
|
leverage and expand our relationships with research institutes, academic institutions and biotechnology companies, including the specific strategic relationships that we have developed with Israeli research and academic institutions, to identify and in-license promising therapeutic
|
Recent Developments
In-Licensing
In September 2012, we announced that we had entered into an agreement with Biokine Therapeutics Ltd., or Biokine, to in-license the rights to BL-8040 for the treatment of AML, as well as other types of hematological cancer. The closing of the transaction was subject to formal approval of the OCS. The approval of the OCS was obtained in January 2013, and therefore the transaction has now closed and the license agreement with Biokine has become effective according to its terms.
Clinical and Pre-Clinical Development
In October 2012, we announced that a recent analysis of the results from the phase 2b EAGLE trial for BL-1020 indicates that BL-1020 demonstrated a significant increase in efficacy at improving cognitive impairment associated with this condition, as compared to the original analysis of the study. The new analysis, which was performed by an outside research group, specifically takes into account effects of the circadian rhythm (i.e., 24-hour time cycle) on cognitive function of the subjects. Results of the re-analysis clearly show that when the time of day for administration of the neurocognitive Brief Assessment of Cognition in Schizophrenia test was consistent between visits, the beneficial effect of BL-1020 on cognitive function was even more pronounced than the original analysis. Specifically, the original analysis for all patients in the study showed an effect size of 0.40 for BL-1020 versus placebo and an effect size of 0.39 for BL-1020 versus Risperidone. However, according to the re-analysis, for the subset of patients with consistent testing times, the effect size increased significantly, to 0.97 for BL-1020 versus placebo and 0.57 for BL-1020 versus Risperidone. These results mean that the beneficial effect of BL-1020 on cognitive function, when compared to the original analysis, more than doubled versus placebo and increased by almost 50% versus Risperidone.
In October 2012, we announced that we intend to conduct an interim analysis of the phase 2/3 CLARITY trial for BL-1020. The interim analysis, which is expected to be finalized during the week of March 18,2013, will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India. The primary endpoint of the analysis will be the six-week effect of the drug on cognitive function, which is a principal deficit in schizophrenia patients.
|
In October 2012, we announced that we had successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and that we plan to commence a phase 1/2 safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.
Patent Protection
In September 2012, we received a Notice of Allowance from the United States Patent and Trademark Office claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia. The patent, when granted, will be valid until at least 2031, without taking into account any possible extension periods, which is nine years longer than the granted patent coverage of BL-1020 previously reported by us.
The Offering
After the closing of this offering, there will be 214,357,168 Ordinary Shares outstanding. The number of Ordinary Shares outstanding after this offering is based on 187,690,498 Ordinary Shares outstanding as of February 5, 2013 and excludes (i) 16,000,000 Ordinary Shares represented by ADSs issuable upon exercise of the Warrants offered pursuant to this prospectus supplement, (ii) 26,221,505 Ordinary Shares issuable upon the exercise of outstanding warrants as of February 5, 2013, at an exercise price of $0.36 per share, and (iii) 13,532,510 Ordinary Shares issuable upon the exercise of outstanding options as of February 5, 2013, at an average exercise price of $0.38 per share.
Our Corporate Information
Our principal executive offices are located at 19 Hartum Street, Jerusalem 91450 Israel, and our telephone number is +972-2-548-9100. Our website is www.biolinerx.com. Information contained in our website is not incorporated by reference into and does not constitute part of this prospectus supplement.
|
|
·
|
the initiation, timing, progress and results of our preclinical studies, clinical trials, and other therapeutic candidate development efforts;
|
|
·
|
our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;
|
|
·
|
our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;
|
|
·
|
the clinical development, commercialization, and market acceptance of our therapeutic candidates;
|
|
·
|
our ability to establish and maintain corporate collaborations;
|
|
·
|
the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;
|
|
·
|
the implementation of our business model, strategic plans for our business and therapeutic candidates;
|
|
·
|
the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;
|
|
·
|
estimates of our expenses, future revenues, capital requirements and our needs for additional financing; and
|
|
·
|
competitive companies, technologies and our industry; and
|
|
·
|
statements as to the impact of the political and security situation in Israel on our business.
|
|
·
|
a therapeutic candidate or medical device may not prove safe or efficacious;
|
|
·
|
the results with respect to any therapeutic candidate may not confirm the positive results from earlier preclinical studies or clinical trials;
|
|
·
|
the results may not meet the level of statistical significance required by the U.S. Food and Drug Administration, or FDA, or other regulatory authorities; and
|
|
·
|
the results will justify only limited and/or restrictive uses, including the inclusion of warnings and contraindications, which could significantly limit the marketability and profitability of the therapeutic candidate.
|
|
·
|
our inability to recruit and retain adequate numbers of effective sales and marketing personnel;
|
|
·
|
the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe our therapeutic candidates;
|
|
·
|
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and
|
|
·
|
unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.
|
|
·
|
we may not be able to control the amount and timing of resources that our licensees devote to our therapeutic candidates;
|
|
·
|
our licensees may experience financial difficulties;
|
|
·
|
our licensees may fail to secure adequate commercial supplies of our therapeutic candidates upon marketing approval, if at all;
|
|
·
|
our future revenues will depend heavily on the efforts of our licensees;
|
|
·
|
business combinations or significant changes in a licensee’s business strategy may adversely affect the licensee’s willingness or ability to complete its obligations under any arrangement with us;
|
|
·
|
a licensee could move forward with a competing therapeutic candidate developed either independently or in collaboration with others, including our competitors; and
|
|
·
|
out-licensing arrangements are often terminated or allowed to expire, which would delay the development and may increase the development costs of our therapeutic candidates.
|
|
·
|
attract suitable licensees on reasonable terms;
|
|
·
|
obtain and maintain necessary intellectual property rights to our therapeutic candidates;
|
|
·
|
where appropriate, enter into arrangements with third parties to manufacture our products, if any, on our behalf; and
|
|
·
|
deploy sales and marketing resources effectively or enter into arrangements with third parties to provide these services.
|
|
·
|
delays in securing clinical investigators or trial sites for the clinical trials;
|
|
·
|
delays in obtaining institutional review board and other regulatory approvals to commence a clinical trial;
|
|
·
|
slower than anticipated patient recruitment and enrollment;
|
|
·
|
negative or inconclusive results from clinical trials;
|
|
·
|
unforeseen safety issues;
|
|
·
|
uncertain dosing issues;
|
|
·
|
an inability to monitor patients adequately during or after treatment; and
|
|
·
|
problems with investigator or patient compliance with the trial protocols.
|
|
·
|
reliance on the third party for regulatory compliance and quality assurance;
|
|
·
|
limitations on supply availability resulting from capacity and scheduling constraints of the third parties;
|
|
·
|
impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet customer demands;
|
|
·
|
the possible breach of the manufacturing agreement by the third party because of factors beyond our control; and
|
|
·
|
the possible termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us.
|
|
·
|
restrictions on such product, manufacturer or manufacturing process;
|
|
·
|
warning letters from the FDA or other regulatory authorities;
|
|
·
|
withdrawal of the product from the market;
|
|
·
|
suspension or withdrawal of regulatory approvals;
|
|
·
|
refusal to approve pending applications or supplements to approved applications that we or our licensees submit;
|
|
·
|
voluntary or mandatory recall;
|
|
·
|
fines;
|
|
·
|
refusal to permit the import or export of our products;
|
|
·
|
product seizure or detentions;
|
|
·
|
injunctions or the imposition of civil or criminal penalties; or
|
|
·
|
adverse publicity.
|
|
·
|
difficulty in large-scale manufacturing;
|
|
·
|
low market acceptance by physicians, healthcare payors, patients and the medical community as a result of lower demonstrated clinical safety or efficacy compared to other products, prevalence and severity of adverse side effects, or other potential disadvantages relative to alternative treatment methods;
|
|
·
|
insufficient or unfavorable levels of reimbursement from government or third-party payors;
|
|
·
|
infringement on proprietary rights of others for which we or our licensees have not received licenses;
|
|
·
|
incompatibility with other therapeutic products;
|
|
·
|
other potential advantages of alternative treatment methods;
|
|
·
|
ineffective marketing and distribution support;
|
|
·
|
lack of cost-effectiveness; or
|
|
·
|
timing of market introduction of competitive products.
|
|
·
|
a covered benefit under its health plan;
|
|
·
|
safe, effective and medically necessary;
|
|
·
|
appropriate for the specific patient;
|
|
·
|
cost-effective; and
|
|
·
|
neither experimental nor investigational.
|
|
·
|
announcements of technological innovations or new products by us or others;
|
|
·
|
announcements by us of significant acquisitions, strategic partnerships, in-licensing, out-licensing, joint ventures or capital commitments;
|
|
·
|
expiration or terminations of licenses, research contracts or other collaboration agreements;
|
|
·
|
public concern as to the safety of drugs we, our licensees or others develop;
|
|
·
|
general market conditions;
|
|
·
|
the volatility of market prices for shares of biotechnology companies generally;
|
|
·
|
success of research and development projects;
|
|
·
|
departure of key personnel;
|
|
·
|
developments concerning intellectual property rights or regulatory approvals;
|
|
·
|
variations in our and our competitors’ results of operations;
|
|
·
|
changes in earnings estimates or recommendations by securities analysts, if our Ordinary Shares or ADSs are covered by analysts;
|
|
·
|
changes in government regulations or patent decisions;
|
|
·
|
developments by our licensees; and
|
|
·
|
general market conditions and other factors, including factors unrelated to our operating performance.
|
|
·
|
the failure to obtain regulatory approval or achieve commercial success of our therapeutic candidates, including BL-1020, BL-1040, BL-5010, BL-7040, BL-8040 and BL-1021;
|
|
·
|
our success in effecting out-licensing arrangements with third-parties;
|
|
·
|
our success in establishing other out-licensing arrangements;
|
|
·
|
the success of our licensees in selling products that utilize our technologies;
|
|
·
|
the results of our preclinical studies and clinical trials for our earlier stage therapeutic candidates, and any decisions to initiate clinical trials if supported by the preclinical results;
|
|
·
|
the costs, timing and outcome of regulatory review of our therapeutic candidates that progress to clinical trials;
|
|
·
|
the costs of establishing or acquiring specialty sales, marketing and distribution capabilities, if any of our therapeutic candidates are approved, and we decide to commercialize them ourselves;
|
|
·
|
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;
|
|
·
|
the extent to which we acquire or invest in businesses, products or technologies and other strategic relationships; and
|
|
·
|
the costs of financing unanticipated working capital requirements and responding to competitive pressures.
|
NIS per U.S. $
|
||||||||||||||||
Year Ended December 31,
|
High
|
Low
|
Average
|
Period End
|
||||||||||||
2012
|
4.084 | 3.700 | 3.844 | 3.733 | ||||||||||||
2011
|
3.821 | 3.363 | 3.578 | 3.821 | ||||||||||||
2010
|
3.894 | 3.549 | 3.730 | 3.549 | ||||||||||||
2009
|
4.256 | 3.690 | 3.923 | 3.775 | ||||||||||||
2008
|
4.022 | 3.230 | 3.586 | 3.802 | ||||||||||||
2007
|
4.342 | 3.830 | 4.110 | 3.846 |
NIS per U.S. $
|
||||||||||||||||
Month
|
High
|
Low
|
Average
|
Period End
|
||||||||||||
February 2013 (through February 5, 2013)
|
3.691 | 3.682 | 3.686 | 3.691 | ||||||||||||
January 2013
|
3.791 | 3.714 | 3.739 | 3.728 | ||||||||||||
December 2012
|
3.835 | 3.726 | 3.777 | 3.733 | ||||||||||||
November 2012
|
3.952 | 3.810 | 3.894 | 3.810 | ||||||||||||
October 2012
|
3.895 | 3.792 | 3.851 | 3.878 | ||||||||||||
September 2012
|
4.029 | 3.887 | 3.959 | 3.912 | ||||||||||||
August 2012
|
4.061 | 3.950 | 4.012 | 4.026 |
NIS
|
U.S.$
|
|||||||||||||||
Price Per
Ordinary Share
|
Price Per
Ordinary Share
|
|||||||||||||||
High
|
Low
|
High
|
Low
|
|||||||||||||
Annual:
|
||||||||||||||||
2012
|
2.12 | 0.89 | 0.56 | 0.23 | ||||||||||||
2011
|
3.24 | 1.13 | 0.91 | 0.30 | ||||||||||||
2010
|
4.75 | 2.86 | 1.26 | 0.80 | ||||||||||||
2009
|
5.68 | 0.86 | 1.53 | 0.23 | ||||||||||||
2008
|
4.25 | 0.69 | 1.10 | 0.17 | ||||||||||||
2007 (from February 8, 2007)
|
6.65 | 3.80 | 1.57 | 0.89 | ||||||||||||
Quarterly:
|
||||||||||||||||
Fourth Quarter 2012
|
1.34 | 0.94 | 0.34 | 0.25 | ||||||||||||
Third Quarter 2012
|
1.18 | 0.91 | 0.30 | 0.23 | ||||||||||||
Second Quarter 2012
|
1.12 | 0.89 | 0.30 | 0.23 | ||||||||||||
First Quarter 2012
|
2.12 | 1.06 | 0.56 | 0.28 | ||||||||||||
Fourth Quarter 2011
|
1.48 | 1.14 | 0.41 | 0.30 | ||||||||||||
Third Quarter 2011
|
1.92 | 1.13 | 0.56 | 0.30 | ||||||||||||
Second Quarter 2011
|
2.54 | 1.58 | 0.74 | 0.45 | ||||||||||||
First Quarter 2011
|
3.24 | 2.15 | 0.91 | 0.60 | ||||||||||||
Fourth Quarter 2010
|
3.59 | 2.86 | 0.99 | 0.80 | ||||||||||||
Third Quarter 2010
|
3.82 | 3.21 | 1.01 | 0.87 | ||||||||||||
Most Recent Six Months:
|
||||||||||||||||
February 2013 (through February 5, 2013)
|
1.80 | 1.45 | 0.49 | 0.39 | ||||||||||||
January 2013
|
1.73 | 0.97 | 0.41 | 0.26 | ||||||||||||
December 2012
|
1.13 | 0.94 | 0.30 | 0.25 | ||||||||||||
November 2012
|
1.23 | 1.04 | 0.32 | 0.27 | ||||||||||||
October 2012
|
1.34 | 0.97 | 0.34 | 0.25 | ||||||||||||
September 2012
|
1.04 | 0.92 | 0.28 | 0.22 | ||||||||||||
August 2012
|
1.18 | 0.95 | 0.30 | 0.24 |
U.S.$
|
||||||||
Price Per
ADS
|
||||||||
High
|
Low
|
|||||||
Annual:
|
||||||||
2012
|
5.55 | 2.23 | ||||||
2011 (from July 25, 2011)
|
5.59 | 2.75 | ||||||
Quarterly:
|
||||||||
Fourth Quarter 2012
|
3.35 | 2.47 | ||||||
Third Quarter 2012
|
3.00 | 2.23 | ||||||
Second Quarter 2012
|
2.85 | 2.30 | ||||||
First Quarter 2012
|
5.55 | 2.75 | ||||||
Fourth Quarter 2011
|
4.21 | 3.01 | ||||||
Third Quarter 2011(from July 25, 2011)
|
5.59 | 2.75 | ||||||
Most Recent Six Months:
|
||||||||
February 2013 (through February 5, 2013)
|
4.75 | 3.94 | ||||||
January 2013
|
4.74 | 2.60 | ||||||
December 2012
|
3.05 | 2.47 | ||||||
November 2012
|
3.16 | 2.55 | ||||||
October 2012
|
3.35 | 2.55 | ||||||
September 2012
|
2.76 | 2.25 | ||||||
August 2012
|
2.84 | 2.23 |
|
·
|
a fund for joint investments in trust (i.e., mutual fund), as such term is defined in the Law for Joint Investments in Trust, 5754-1994, or a management company of such a fund;
|
|
·
|
a provident fund as defined in the Control of the Financial Services (Provident Funds) Law 5765-2005, or a management company of such a fund;
|
|
·
|
an insurer, as defined in the Law for Oversight of Insurance Transactions, 5741-1981;
|
|
·
|
a banking entity or satellite entity, as such terms are defined in the Banking Law (Licensing), 5741-1981, other than a joint services company, acting for their own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
|
|
·
|
a company that is licensed as a portfolio manager, as such term is defined in Section 8(b) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
|
|
·
|
an investment advisor or investment distributer, as such term is defined in Section 7(c) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account;
|
|
·
|
a member of the Tel Aviv Stock Exchange, acting on its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law 1968;
|
|
·
|
an underwriter fulfilling the conditions of Section 56(c) of the Securities Law, 5728-1968, acting on its own account;
|
|
·
|
a venture capital fund (defined as an entity primarily involved in investments in companies which, at the time of investment, (i) are primarily engaged in research and development or manufacture of new technological products or processes and (ii) involve above-average risk);
|
|
·
|
an entity fully owned by investors of the type listed in Section 15A(b) of the Securities Law 1968;
|
|
·
|
an entity, other than an entity formed for the purpose of purchasing securities in this offering, in which the shareholders equity is in excess of NIS 50 million; and
|
|
·
|
An individual, fulfilling the conditions of section 9 to the supplement to the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account, and for this matter, the Section 9 to the supplement shall be referred to instead of "as an eligible client for the meaning of this law", as "as an investor for the meaning of Section15A(b)(1) of the Securities Law 1968.
|
BioLineRx Ltd.
P.O. Box 45158, 19 Hartum Street
Jerusalem 91450, Israel
Attention: Corporate Secretary
Tel.: +972-2-548-9100
e-mail: info@BioLineRx.com
|
|
·
|
the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;
|
|
·
|
the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;
|
|
·
|
adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;
|
|
·
|
the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;
|
|
·
|
the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;
|
|
·
|
an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and
|
|
·
|
the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.
|
|
·
|
American Depositary Shares (“ADSs”);
|
|
·
|
ordinary shares;
|
·
|
debt securities;
|
|
·
|
warrants to purchase ADSs; and
|
|
·
|
units consisting of two or more of these classes or series of securities.
|
1 | |
2
|
|
2
|
|
3 | |
4
|
|
5
|
|
6
|
|
7
|
|
8
|
|
9
|
|
14
|
|
17
|
|
30
|
|
32
|
|
33
|
|
34 | |
37
|
|
37
|
|
38
|
This summary highlights selected information contained elsewhere in this prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our ADSs or our ordinary shares. You should read this summary together with the entire prospectus, including the risks related to our most advanced therapeutic candidates, BL-1020, BL-1040, BL-5010, BL-1021 and BL-7040, our business, our industry, investing in our ordinary shares and our location in Israel, that we describe under “Risk Factors,” and our consolidated financial statements and the related notes, which are incorporated by reference herein, before making an investment in our ordinary shares.
Our Business
We are a clinical stage biopharmaceutical development company dedicated to identifying, in-licensing and developing therapeutic candidates that have advantages over currently available therapies or that address unmet medical needs. Our current development pipeline consists of five clinical-stage therapeutic candidates: BL-1020, an orally available drug that we believe may be the first antipsychotic therapeutic to improve cognitive function in schizophrenia patients; BL-1021, a new chemical entity in development for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-1040, a novel polymer solution for use in the prevention of cardiac remodeling following an acute myocardial infarction, or AMI; BL-5010, a novel formulation for the non-surgical removal of skin lesions; and BL-7040, an oligonucleotide for the treatment of Inflammatory Bowel Disease (IBD). In addition, we have 11 therapeutic candidates in the preclinical stages of development. We generate our pipeline by systematically identifying, rigorously validating and in-licensing therapeutic candidates that we believe exhibit a relatively high probability of therapeutic and commercial success. None of our therapeutic candidates has been approved for marketing and, to date, there have been no commercial sales of any of our therapeutic candidates. Our strategy includes commercializing our therapeutic candidates through out-licensing arrangements with biotechnology and pharmaceutical companies and evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.
Our Product Pipeline
The table below summarizes our current pipeline of therapeutic candidates, as well as the target indication and status of each candidate.
|
|
·
|
the initiation, timing, progress and results of our preclinical studies, clinical trials, and other therapeutic candidate development efforts;
|
|
·
|
our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;
|
|
·
|
our receipt of regulatory approvals for our therapeutic candidates, and the timing of other regulatory filings and approvals;
|
|
·
|
the clinical development, commercialization, and market acceptance of our therapeutic candidates;
|
|
·
|
our ability to establish and maintain corporate collaborations;
|
|
·
|
the interpretation of the properties and characteristics of our therapeutic candidates and of the results obtained with our therapeutic candidates in preclinical studies or clinical trials;
|
|
·
|
the implementation of our business model, strategic plans for our business and therapeutic candidates;
|
|
·
|
the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and our ability to operate our business without infringing the intellectual property rights of others;
|
|
·
|
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
|
|
·
|
competitive companies, technologies and our industry; and
|
|
·
|
statements as to the impact of the political and security situation in Israel on our business.
|
NIS per U.S. $
|
||||||||||||
Year Ended December 31,
|
High
|
Low
|
Average
|
Period End
|
||||||||
2011
|
3.821 | 3.363 | 3.578 | 3.821 | ||||||||
2010
|
3.894 | 3.549 | 3.730 | 3.549 | ||||||||
2009
|
4.256 | 3.690 | 3.923 | 3.775 | ||||||||
2008
|
4.022 | 3.230 | 3.586 | 3.802 | ||||||||
2007
|
4.342 | 3.830 | 4.110 | 3.846 |
NIS per U.S. $
|
||||||||||||
Month
|
High
|
Low
|
Average
|
Period End
|
||||||||
August 2012 (through August 8, 2012)
|
4.007
|
3.970
|
3.988
|
3.997
|
||||||||
July 2012
|
4.084
|
3.913
|
3.985
|
3.997
|
||||||||
June 2012
|
3.947 | 3.856 | 3.893 | 3.923 | ||||||||
May 2012
|
3.881 | 3.768 | 3.826 | 3.881 | ||||||||
April 2012
|
3.769 | 3.715 | 3.750 | 3.750 | ||||||||
March 2012
|
3.814 | 3.715 | 3.767 | 3.715 | ||||||||
February 2012
|
3.803 | 3.700 | 3.740 | 3.766 |
NIS
|
U.S.$
|
|||||||||||
Price Per
Ordinary Share
|
Price Per
Ordinary Share
|
|||||||||||
High
|
Low
|
High
|
Low
|
|||||||||
Annual:
|
||||||||||||
2011
|
3.24 | 1.13 | 0.91 | 0.30 | ||||||||
2010
|
4.75 | 2.86 | 1.26 | 0.80 | ||||||||
2009
|
5.68 | 0.86 | 1.53 | 0.23 | ||||||||
2008
|
4.25 | 0.69 | 1.10 | 0.17 | ||||||||
2007 (from February 8, 2007)
|
6.65 | 3.80 | 1.57 | 0.89 | ||||||||
Quarterly:
|
||||||||||||
Second Quarter 2012
|
1.12 | 0.89 | 0.30 | 0.23 | ||||||||
First Quarter 2012
|
2.12 | 1.06 | 0.56 | 0.28 | ||||||||
Fourth Quarter 2011
|
1.48 | 1.14 | 0.41 | 0.30 | ||||||||
Third Quarter 2011
|
1.92 | 1.13 | 0.56 | 0.30 | ||||||||
Second Quarter 2011
|
2.54 | 1.58 | 0.74 | 0.45 | ||||||||
First Quarter 2011
|
3.24 | 2.15 | 0.91 | 0.60 | ||||||||
Fourth Quarter 2010
|
3.59 | 2.86 | 0.99 | 0.80 | ||||||||
Third Quarter 2010
|
3.82 | 3.21 | 1.01 | 0.87 | ||||||||
Second Quarter 2010
|
4.69 | 3.00 | 1.27 | 0.78 | ||||||||
First Quarter 2010
|
4.75 | 3.80 | 1.26 | 1.03 | ||||||||
Most Recent Six Months:
|
||||||||||||
August 2012 (through August 8, 2012)
|
1.16 |
1.10
|
0.29
|
0.28
|
||||||||
July 2012 |
1.18
|
0.95
|
0.30
|
0.24
|
||||||||
June 2012
|
0.97 | 0.90 | 0.25 | 0.23 | ||||||||
May 2012
|
1.11 | 0.89 | 0.26 | 0.23 | ||||||||
April 2012
|
1.12 | 1.01 | 0.30 | 0.27 | ||||||||
March 2012
|
1.21 | 1.06 | 0.32 | 0.28 | ||||||||
February 2012
|
1.87 | 1.21 | 0.50 | 0.32 |
U.S.$
|
||||||
Price Per
ADS
|
||||||
High
|
Low
|
|||||
Annual:
|
||||||
2011 (from July 25, 2011)
|
5.59 | 2.75 | ||||
Quarterly:
|
||||||
Second Quarter 2012
|
2.85 | 2.30 | ||||
First Quarter 2012
|
5.55 | 2.75 | ||||
Fourth Quarter 2011
|
4.21 | 3.01 | ||||
Third Quarter 2011(from July 25, 2011)
|
5.59 | 2.75 | ||||
Most Recent Six Months:
|
||||||
August 2012 (through August 8, 2012) |
2.85
|
2.60
|
||||
July 2012
|
3.00
|
2.41
|
||||
June 2012
|
2.57 | 2.30 | ||||
May 2012
|
2.81 | 2.32 | ||||
April 2012
|
2.85 | 2.64 | ||||
March 2012
|
3.27 | 2.75 | ||||
February 2012
|
4.44 | 3.03 |
Year Ended December 31,
|
Three Months Ended March 31,
|
|||||||||
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
|||||
(59,419)
|
(114,849)
|
(61,518)
|
24.58x
|
(50,186)
|
(17,932)
|
|
·
|
amendments to our Articles of Association;
|
|
·
|
appointment or termination of our auditors;
|
|
·
|
appointment of directors and appointment and dismissal of external directors;
|
|
·
|
approval of acts and transactions requiring general meeting approval pursuant to the Israeli Companies Law;
|
|
·
|
director compensation, indemnification and change of the principal executive officer;
|
|
·
|
increases or reductions of our authorized share capital;
|
|
·
|
a merger; and
|
|
·
|
the exercise of our Board of Director’s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
|
|
·
|
an appointment or removal of directors;
|
|
·
|
an approval of transactions with office holders or interested or related parties;
|
|
·
|
an approval of a merger or any other matter in respect of which there is a provision in the articles of association providing that decisions of the general meeting may also be passed by written ballot;
|
|
·
|
authorizing the chairman of the board of directors or his relative to act as the company’s chief executive officer or act with such authority; or authorize the company’s chief executive officer or his relative to act as the chairman of the board of directors or act with such authority; and
|
|
·
|
other matters which may be prescribed by Israel’s Minister of Justice.
|
|
·
|
make the rights available to all or certain holders of ADSs, by means of warrants or otherwise, if lawful and practically feasible; or
|
|
·
|
if it is not lawful or practically feasible to make the rights available, attempt to sell those rights or warrants or other instruments.
|
|
·
|
collect dividends and other distributions pertaining to deposited securities;
|
|
·
|
sell rights as described under the heading “Dividends, other distributions and rights — Rights to subscribe for additional shares and other rights” above; and
|
|
·
|
deliver deposited securities, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any rights or other property, in exchange for surrendered ADSs.
|
|
·
|
taxes and other governmental charges;
|
|
·
|
any applicable transfer or registration fees;
|
|
·
|
certain cable, telex and facsimile transmission charges as provided in the Deposit Agreement;
|
|
·
|
any expenses incurred in the conversion of foreign currency;
|
|
·
|
a fee of $5.00 or less per 100 ADSs (or a portion thereof) for the execution and delivery of ADSs and the surrender of ADSs;
|
|
·
|
a fee of $.05 or less per ADS (or portion thereof) for any cash distribution made pursuant to the Deposit Agreement;
|
|
·
|
a fee for the distribution of securities pursuant to the Deposit Agreement;
|
|
·
|
in addition to any fee charged under clause 6, a fee of $.05 or less per ADS (or portion thereof) per annum for depositary services, which will be payable as provided in clause 10 below;
|
|
·
|
a fee for the distribution of proceeds of rights that the Depositary sells pursuant to the Deposit Agreement; and
|
|
·
|
any other charges payable by the Depositary, any of the Depositary's agents, or the agents of the Depositary's agents in connection with the servicing of Shares or other Deposited Securities.
|
|
·
|
the designation or title of the series of debt securities;
|
|
·
|
the total principal amount of the series of debt securities;
|
|
·
|
the percentage of the principal amount at which the series of debt securities will be offered;
|
|
·
|
the date or dates on which principal will be payable;
|
|
·
|
the rate or rates (which may be either fixed or variable) and/or the method of determining such rate or rates of interest, if any;
|
|
·
|
the date or dates from which any interest will accrue, or the method of determining such date or dates, and the date or dates on which any interest will be payable;
|
|
·
|
whether any interest may be paid by issuing additional securities of the same series in lieu of cash (and the terms upon which any such interest may be paid by issuing additional securities);
|
|
·
|
the terms for redemption, extension or early repayment, if any;
|
|
·
|
the currencies in which the series of debt securities are issued and payable;
|
|
·
|
whether the amount of payments of principal, premium or interest, if any, on a series of debt securities will be determined with reference to an index, formula or other method (which could be based on one or more currencies, commodities, equity indices or other indices) and how these amounts will be determined;
|
|
·
|
the place or places, if any, other than or in addition to the Borough of Manhattan in the City of New York, of payment, transfer, conversion and/or exchange of the debt securities;
|
|
·
|
the denominations in which the offered debt securities will be issued (if other than $1,000 and any integral multiple thereof for registered securities);
|
|
·
|
the provision for any sinking fund;
|
|
·
|
any restrictive covenants;
|
|
·
|
any Events of Default;
|
|
·
|
whether the series of debt securities are issuable in certificated form;
|
|
·
|
any provisions for defeasance or covenant defeasance;
|
|
·
|
any special Israeli and/or U.S. federal income tax implications, including, if applicable, Israeli and/or U.S. federal income tax considerations relating to original issue discount;
|
|
·
|
whether and under what circumstances we will pay additional amounts in respect of any tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities rather than pay the additional amounts (and the terms of this option);
|
|
·
|
any provisions for convertibility or exchangeability of the debt securities into or for any other securities;
|
|
·
|
whether the debt securities are subject to subordination and the terms of such subordination;
|
|
·
|
whether the debt securities are secured or unsecured and the terms of any security interests;
|
|
·
|
the listing, if any, on a securities exchange; and
|
|
·
|
any other terms.
|
|
·
|
how it handles securities payments and notices;
|
|
·
|
whether it imposes fees or charges;
|
|
·
|
how it would handle a request for the holders’ consent, if ever required;
|
|
·
|
whether and how you can instruct it to send you debt securities registered in your own name so you can be a holder, if that is permitted in the future for a particular series of debt securities;
|
|
·
|
how it would exercise rights under the debt securities if there were a default or other event triggering the need for holders to act to protect their interests; and
|
|
·
|
if the debt securities are in book-entry form, how the depositary’s rules and procedures will affect these matters.
|
|
·
|
An investor cannot cause the debt securities to be registered in his or her name, and cannot obtain certificates for his or her interest in the debt securities, except in the special situations we describe below.
|
|
·
|
An investor will be an indirect holder and must look to his or her own bank or broker for payments on the debt securities and protection of his or her legal rights relating to the debt securities, as we describe under “Issuance of Securities in Registered Form” above.
|
|
·
|
An investor may not be able to sell interests in the debt securities to some insurance companies and other institutions that are required by law to own their securities in non-book-entry form.
|
|
·
|
An investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the debt securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective.
|
|
·
|
The depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in a global security. We and the trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way.
|
|
·
|
If we redeem less than all the debt securities of a particular series being redeemed, DTC’s practice is to determine by lot the amount to be redeemed from each of its participants holding that series.
|
|
·
|
An investor is required to give notice of exercise of any option to elect repayment of its debt securities, through its participant, to the applicable trustee and to deliver the related debt securities by causing its participant to transfer its interest in those debt securities, on DTC’s records, to the applicable trustee.
|
|
·
|
DTC requires that those who purchase and sell interests in a global security deposited in its book-entry system use immediately available funds. Your broker or bank may also require you to use immediately available funds when purchasing or selling interests in a global security.
|
|
·
|
Financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the debt securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.
|
|
·
|
We do not pay interest on a debt security of the series within 30 days of its due date.
|
|
·
|
We do not pay the principal of, or any premium on, a debt security of the series on its due date.
|
|
·
|
We do not deposit any sinking fund payment in respect of debt securities of the series within 2 business days of its due date.
|
|
·
|
We remain in breach of a covenant in respect of debt securities of the series for 60 days after we receive a written notice of default stating we are in breach. The notice must be sent by either the trustee or holders of at least 25% of the principal amount of debt securities of the series.
|
|
·
|
We file for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur.
|
|
·
|
Any other Event of Default in respect of debt securities of the series described in the applicable prospectus supplement occurs.
|
|
·
|
You must give your trustee written notice that an Event of Default has occurred and remains uncured.
|
|
·
|
The holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action because of the default and must offer reasonable indemnity to the trustee against the cost and other liabilities of taking that action.
|
|
·
|
The trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity.
|
|
·
|
The holders of a majority in principal amount of the debt securities must not have given the trustee a direction inconsistent with the above notice during that 60-day period.
|
|
·
|
the payment of principal, any premium or interest or
|
|
·
|
in respect of a covenant that cannot be modified or amended without the consent of each holder.
|
|
·
|
Where we merge out of existence or sell our assets, the resulting entity must agree to be legally responsible for our obligations under the debt securities.
|
|
·
|
The merger or sale of assets must not cause a default on the debt securities and we must not already be in default (unless the merger or sale would cure the default). For purposes of this no-default test, a default would include an Event of Default that has occurred and has not been cured, as described under “Events of Default” above. A default for this purpose would also include any event that would be an Event of Default if the requirements for giving us a notice of default or our default having to exist for a specific period of time were disregarded.
|
|
·
|
We must deliver certain certificates and documents to the trustee.
|
|
·
|
We must satisfy any other requirements specified in the prospectus supplement relating to a particular series of debt securities.
|
|
·
|
change the stated maturity of the principal of, or interest on, a debt security;
|
|
·
|
reduce any amounts due on a debt security;
|
|
·
|
reduce the amount of principal payable upon acceleration of the maturity of a security following a default;
|
|
·
|
adversely affect any right of repayment at the holder’s option;
|
|
·
|
change the place (except as otherwise described in the prospectus or prospectus supplement) or currency of payment on a debt security;
|
|
·
|
impair your right to sue for payment;
|
|
·
|
adversely affect any right to convert or exchange a debt security in accordance with its terms;
|
|
·
|
modify the subordination provisions in the indenture in a manner that is adverse to holders of the debt securities;
|
|
·
|
reduce the percentage of holders of debt securities whose consent is needed to modify or amend the indenture;
|
|
·
|
reduce the percentage of holders of debt securities whose consent is needed to waive compliance with certain provisions of the indenture or to waive certain defaults;
|
|
·
|
modify any other aspect of the provisions of the indenture dealing with supplemental indentures, modification and waiver of past defaults, changes to the quorum or voting requirements or the waiver of certain covenants; and
|
|
·
|
change any obligation we have to pay additional amounts.
|
|
·
|
If the change affects only one series of debt securities, it must be approved by the holders of a majority in principal amount of that series.
|
|
·
|
If the change affects more than one series of debt securities issued under the same indenture, it must be approved by the holders of a majority in principal amount of all of the series affected by the change, with all affected series voting together as one class for this purpose.
|
|
·
|
For original issue discount securities, we will use the principal amount that would be due and payable on the voting date if the maturity of these debt securities were accelerated to that date because of a default.
|
|
·
|
For debt securities whose principal amount is not known (for example, because it is based on an index), we will use the principal face amount at original issuance or a special rule for that debt security described in the prospectus supplement.
|
|
·
|
For debt securities denominated in one or more foreign currencies, we will use the U.S. dollar equivalent.
|
|
·
|
If the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and United States government or United States government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.
|
|
·
|
We must deliver to the trustee a legal opinion of our counsel confirming that, under current United States federal income tax law, we may make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity.
|
|
·
|
We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as amended, and a legal opinion and officers’ certificate stating that all conditions precedent to covenant defeasance have been complied with.
|
|
·
|
Defeasance must not result in a breach of the indenture or any of our other material agreements.
|
|
·
|
Satisfy the conditions for covenant defeasance contained in any supplemental indentures.
|
|
·
|
If the debt securities of the particular series are denominated in U.S. dollars, we must deposit in trust for the benefit of all holders of such debt securities a combination of money and United States government or United States government agency notes or bonds that will generate enough cash to make interest, principal and any other payments on the debt securities on their various due dates and any mandatory sinking fund payments or analogous payments.
|
|
·
|
We must deliver to the trustee a legal opinion confirming that there has been a change in current United States federal tax law or an IRS ruling that allows us to make the above deposit without causing you to be taxed on the debt securities any differently than if we did not make the deposit and just repaid the debt securities ourselves at maturity. Under current United States federal tax law, the deposit and our legal release from the debt securities would be treated as though we paid you your share of the cash and notes or bonds at the time the cash and notes or bonds were deposited in trust in exchange for your debt securities and you would recognize gain or loss on the debt securities at the time of the deposit.
|
|
·
|
We must deliver to the trustee a legal opinion of our counsel stating that the above deposit does not require registration by us under the 1940 Act, as amended, and a legal opinion and officers’ certificate stating that all conditions precedent to defeasance have been complied with.
|
|
·
|
Defeasance must not result in a breach of the indenture or any of our other material agreements.
|
|
·
|
Satisfy the conditions for covenant defeasance contained in any supplemental indentures.
|
|
·
|
only in fully registered certificated form;
|
|
·
|
without interest coupons, and
|
|
·
|
unless we indicate otherwise in the prospectus supplement, in denominations of $1,000 and amounts that are multiples of $1,000.
|
|
·
|
our indebtedness (including indebtedness of others guaranteed by us), whenever created, incurred, assumed or guaranteed, for money borrowed, that we have designated as “Designated Senior Indebtedness” for purposes of the indenture and in accordance with the terms of the indenture (including any indenture securities designated as Designated Senior Indebtedness), and
|
|
·
|
renewals, extensions, modifications and refinancings of any of this indebtedness.
|
·
|
the offering price;
|
|
·
|
the aggregate number or amount of underlying securities purchasable upon exercise of the warrants and the exercise price;
|
|
·
|
the number of warrants being offered;
|
|
·
|
the date, if any, after which the warrants and the underlying securities will be transferable separately;
|
|
·
|
the date on which the right to exercise the warrants will commence, and the date on which the right will expire (the “Expiration Date”);
|
|
·
|
the number of warrants outstanding, if any;
|
|
·
|
any material Israeli and/or U.S. federal income tax consequences;
|
|
·
|
the terms, if any, on which we may accelerate the date by which the warrants must be exercised; and
|
|
·
|
any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
|
|
·
|
the trading price of the warrants;
|
|
·
|
the price of the underlying securities at that time;
|
|
·
|
the time remaining to expiration; and
|
|
·
|
any related transaction costs.
|
|
·
|
the date, if any, on and after which the units may be transferable separately;
|
|
·
|
whether we will apply to have the units traded on a securities exchange or securities quotation system;
|
|
·
|
any material Israeli and/or U.S. federal income tax consequences; and
|
|
·
|
how, for Israeli and/or U.S. federal income tax purposes, the purchase price paid for the units is to be allocated among the component securities.
|
|
·
|
to or through one or more underwriters or dealers;
|
|
·
|
in short or long transactions;
|
|
·
|
directly to investors; or
|
|
·
|
through agents.
|
|
·
|
in privately negotiated transactions;
|
|
·
|
in one or more transactions at a fixed price or prices, which may be changed from time to time;
|
|
·
|
in “at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise;
|
|
·
|
at prices related to those prevailing market prices; or
|
|
·
|
at negotiated prices.
|
|
·
|
the names of any underwriters, dealers or agents;
|
|
·
|
any agency fees or underwriting discounts or commissions and other items constituting agents’ or underwriters’ compensation;
|
|
·
|
any discounts or concessions allowed or reallowed or paid to dealers;
|
|
·
|
details regarding over-allotment options under which underwriters may purchase additional securities from us, if any;
|
|
·
|
the purchase price of the securities being offered and the proceeds we will receive from the sale;
|
|
·
|
the public offering price; and
|
|
·
|
the securities exchanges on which such securities may be listed, if any.
|
|
·
|
the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;
|
|
·
|
the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;
|
|
·
|
adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;
|
|
·
|
the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;
|
|
·
|
the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;
|
|
·
|
an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and
|
|
·
|
the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.
|